HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
HARROW, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$27.68+0.40 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$12.33 (−30.82%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
HARROW, INC. grew revenue 21.1% to $275.59M over the twelve months to Jun 30, 2026. Operating income fell 119.1% to -$2.75M, moving the operating margin from 6.3% to -1.0%. Free cash flow was $5.02M, up 97.3% from a year earlier.
Revenue
$275.59M
+21.1% vs. a year earlier
Operating income
-$2.75M
-119.1% vs. a year earlier
Free cash flow
$5.02M
+97.3% vs. a year earlier
EPS, diluted
-$0.99
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.03B
- P/E ratio
- –
- Price to sales
- 3.75
- Price to book
- 68.02
- Dividend yield
- –
- Free cash flow yield
- 0.49%
Fundamentals
- Revenue
- $275.59M
- Net income
- -$37.23M
- EPS, diluted
- -$0.99
- Free cash flow
- $5.02M
- Book value per share
- $0.41
- Diluted shares
- 37M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$275.59M+21.1% YoY
Gross profit
$201.96M+19.0% YoY
Operating income
-$2.75M-119.1% YoY
Net income
-$37.23M
EPS, diluted
-$0.99
Free cash flow
$5.02M+97.3% YoY
Reported periodTrailing twelve months